首个抗肿瘤候选植物药“YIV-906”与索拉非尼联合治疗肝细胞癌的IIb期临床试验正式启动
06 avr. 2020 07h00 HE
|
Yiviva
—— 利用整合系统生物学方法，由耶鲁大学郑永齐教授和医起共同开发的首个抗肿瘤候选植物药 中国上海，美国纽约, April 06, 2020 (GLOBE NEWSWIRE) -- 生物制药创新企业医起医药科技有限公司（Yiviva Inc.），在2020年初正式启动了YIV-906联合索拉非尼治疗乙型肝炎相关性肝细胞癌（HCC）的一线疗法IIb期研究，并于今年三月迎来了第一位受试者。 ...
Plasma de convalescent pour le traitement de la COVID-19
02 avr. 2020 09h15 HE
|
Société canadienne du sang
OTTAWA, 02 avr. 2020 (GLOBE NEWSWIRE) -- La Société canadienne du sang travaille activement avec Santé Canada et la communauté internationale de la recherche afin de contribuer à l’effort mondial...
COVID-19 convalescent plasma for patients
02 avr. 2020 09h15 HE
|
Canadian Blood Services
OTTAWA, April 02, 2020 (GLOBE NEWSWIRE) -- Canadian Blood Services is actively working with Health Canada and the international research community to contribute to the global effort to determine if...
Small NJ Biotech Firm, BioAegis Therapeutics, Accelerating Multiple Clinical Trial Submissions for Severe COVID-19 Pneumonia Patients
02 avr. 2020 02h15 HE
|
BioAegis Therapeutics
MORRISTOWN, N.J., April 02, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. is a clinical stage, private company focused on developing therapies for infectious, inflammatory, and degenerative...
BIOCARDIA ANNOUNCES POSITIVE DSMB RECOMMENDATION TO CONTINUE PHASE III PIVOTAL CARDIAMP HEART FAILURE STUDY, AS PLANNED
31 mars 2020 08h00 HE
|
BioCardia, Inc.
SAN CARLOS, Calif., March 31, 2020 (GLOBE NEWSWIRE) -- BioCardia (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced...
INCYSUS THERAPEUTICS TO PRESENT AT THE NYC SPRING ONCOLOGY INVESTOR CONFERENCE
31 mars 2020 07h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, March 31, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a clinical-stage biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell...
ideaPoint and WideTrial Launch Global Expanded Access Platform for COVID-19 Medicines
31 mars 2020 07h00 HE
|
Anaqua
BOSTON, March 31, 2020 (GLOBE NEWSWIRE) -- Anaqua’s ideaPoint, a provider of medical affairs and innovation management solutions, today announced a strategic partnership with clinical data company...
ProQR Announces Positive Findings From an Interim Analysis in the Phase 1/2 trial of QR-421a for Usher Syndrome and Provides Business Update
31 mars 2020 06h00 HE
|
ProQR Therapeutics N.V.
QR-421a showed early and encouraging evidence of activity, with 25% of patients showing a benefit across multiple concordant outcome measures and was well tolerated with no serious adverse...
Translate Bio Provides MRT5005 Program Updates
26 mars 2020 16h30 HE
|
Translate Bio, Inc.
-- FDA grants Rare Pediatric Disease designation for MRT5005 for treatment of cystic fibrosis – -- Response to COVID-19 pandemic anticipated to cause interruptions in certain clinical trial...
First Patient Dosed in EVICTION Trial Evaluating ImCheck’s Lead Anti-Cancer Drug, ICT01: A Novel Gamma Delta T Cell-Activating Immunotherapy
26 mars 2020 06h00 HE
|
ImCheck Therapeutics SAS
FOR IMMEDIATE RELEASE -- First-in-human, international, multi-center trial to test Butyrophylin 3A-targeted antibody in advanced solid and hematologic tumors -- Marseille, France, March 26, 2020 –...